MAIA Historical Balance Sheet

MAIA Stock

USD 2.09 0.01 0.48%

Trend analysis of MAIA Biotechnology balance sheet accounts such as Total Current Liabilities of 2.7 M provides information on MAIA Biotechnology's total assets, liabilities, and equity, which is the actual value of MAIA Biotechnology to its prevalent stockholders. By breaking down trends over time using MAIA Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.

About MAIA Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of MAIA Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. MAIA Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of MAIA Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which MAIA currently owns. An asset can also be divided into two categories, current and non-current.

MAIA Biotechnology Balance Sheet Chart

At present, MAIA Biotechnology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Liabilities Total is expected to grow to about 2.3 M, whereas Total Assets are forecasted to decline to about 7.3 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of MAIA Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in MAIA Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on MAIA Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of MAIA Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from MAIA Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into MAIA Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.At present, MAIA Biotechnology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Liabilities Total is expected to grow to about 2.3 M, whereas Total Assets are forecasted to decline to about 7.3 M.

	2023	2024 (projected)
Short and Long Term Debt Total	533.3K	274.4K
Total Assets	7.6M	7.3M

Short Long Term Debt Total Total Assets

MAIA Biotechnology balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Net Invested Capital	Short Long Term Debt	Capital Stock	Non Current Liabilities Other
Total Assets		0.76	0.71	0.78	0.88	0.76	0.92	0.77	-1.0	-0.77	0.87	1.0	1.0	0.08	0.56	0.81	0.88	0.65	1.0	0.91	0.74	-0.37	0.96	-0.37	0.74	-0.37
Short Long Term Debt Total	0.76		0.91	0.9	0.49	1.0	0.69	0.95	-0.73	-0.77	0.82	0.76	0.76	0.29	0.69	0.72	0.84	0.74	0.76	0.81	0.76	-0.36	0.72	-0.36	0.75	-0.36
Other Current Liab	0.71	0.91		0.99	0.33	0.91	0.79	0.91	-0.71	-0.93	0.92	0.71	0.71	0.53	0.83	0.78	0.94	0.91	0.72	0.87	0.94	-0.6	0.56	-0.6	0.94	-0.6
Total Current Liabilities	0.78	0.9	0.99		0.42	0.9	0.85	0.9	-0.77	-0.94	0.96	0.78	0.78	0.53	0.83	0.8	0.97	0.91	0.79	0.91	0.96	-0.6	0.63	-0.6	0.96	-0.6
Total Stockholder Equity	0.88	0.49	0.33	0.42		0.49	0.67	0.43	-0.87	-0.38	0.59	0.88	0.88	-0.3	0.13	0.6	0.59	0.21	0.87	0.6	0.4	0.05	0.95	0.05	0.38	0.05
Other Liab	0.76	1.0	0.91	0.9	0.49		0.69	0.95	-0.73	-0.77	0.82	0.76	0.76	0.29	0.7	0.72	0.85	0.74	0.76	0.81	0.76	-0.36	0.72	-0.36	0.75	-0.36
Net Tangible Assets	0.92	0.69	0.79	0.85	0.67	0.69		0.78	-0.94	-0.92	0.94	0.92	0.92	0.41	0.78	0.75	0.93	0.84	0.92	0.98	0.86	-0.67	0.77	-0.67	0.88	-0.67
Current Deferred Revenue	0.77	0.95	0.91	0.9	0.43	0.95	0.78		-0.76	-0.87	0.82	0.77	0.77	0.38	0.83	0.72	0.85	0.88	0.77	0.89	0.77	-0.6	0.68	-0.6	0.79	-0.6
Net Debt	-1.0	-0.73	-0.71	-0.77	-0.87	-0.73	-0.94	-0.76		0.78	-0.88	-1.0	-1.0	-0.11	-0.58	-0.8	-0.88	-0.66	-1.0	-0.92	-0.75	0.41	-0.94	0.41	-0.75	0.41
Retained Earnings	-0.77	-0.77	-0.93	-0.94	-0.38	-0.77	-0.92	-0.87	0.78		-0.93	-0.77	-0.77	-0.58	-0.91	-0.78	-0.94	-0.98	-0.78	-0.96	-0.93	0.81	-0.57	0.81	-0.96	0.81
Accounts Payable	0.87	0.82	0.92	0.96	0.59	0.82	0.94	0.82	-0.88	-0.93		0.88	0.88	0.49	0.78	0.8	1.0	0.85	0.88	0.94	0.97	-0.56	0.73	-0.56	0.97	-0.56
Cash	1.0	0.76	0.71	0.78	0.88	0.76	0.92	0.77	-1.0	-0.77	0.88		1.0	0.09	0.56	0.8	0.88	0.65	1.0	0.91	0.74	-0.37	0.96	-0.37	0.75	-0.37
Cash And Short Term Investments	1.0	0.76	0.71	0.78	0.88	0.76	0.92	0.77	-1.0	-0.77	0.88	1.0		0.09	0.56	0.8	0.88	0.65	1.0	0.91	0.74	-0.37	0.96	-0.37	0.75	-0.37
Common Stock Shares Outstanding	0.08	0.29	0.53	0.53	-0.3	0.29	0.41	0.38	-0.11	-0.58	0.49	0.09	0.09		0.79	0.0	0.44	0.67	0.09	0.44	0.61	-0.72	-0.15	-0.72	0.62	-0.72
Non Current Liabilities Total	0.56	0.69	0.83	0.83	0.13	0.7	0.78	0.83	-0.58	-0.91	0.78	0.56	0.56	0.79		0.46	0.77	0.96	0.56	0.85	0.8	-0.89	0.36	-0.89	0.83	-0.89
Other Current Assets	0.81	0.72	0.78	0.8	0.6	0.72	0.75	0.72	-0.8	-0.78	0.8	0.8	0.8	0.0	0.46		0.85	0.68	0.83	0.77	0.76	-0.37	0.72	-0.37	0.76	-0.37
Other Stockholder Equity	0.88	0.84	0.94	0.97	0.59	0.85	0.93	0.85	-0.88	-0.94	1.0	0.88	0.88	0.44	0.77	0.85		0.86	0.89	0.95	0.97	-0.56	0.74	-0.56	0.97	-0.56
Total Liab	0.65	0.74	0.91	0.91	0.21	0.74	0.84	0.88	-0.66	-0.98	0.85	0.65	0.65	0.67	0.96	0.68	0.86		0.66	0.9	0.88	-0.87	0.44	-0.87	0.91	-0.87
Total Current Assets	1.0	0.76	0.72	0.79	0.87	0.76	0.92	0.77	-1.0	-0.78	0.88	1.0	1.0	0.09	0.56	0.83	0.89	0.66		0.91	0.76	-0.38	0.95	-0.38	0.76	-0.38
Short Term Debt	0.91	0.81	0.87	0.91	0.6	0.81	0.98	0.89	-0.92	-0.96	0.94	0.91	0.91	0.44	0.85	0.77	0.95	0.9	0.91		0.88	-0.7	0.77	-0.7	0.9	-0.7
Common Stock	0.74	0.76	0.94	0.96	0.4	0.76	0.86	0.77	-0.75	-0.93	0.97	0.74	0.74	0.61	0.8	0.76	0.97	0.88	0.76	0.88		-0.62	0.55	-0.62	1.0	-0.62
Long Term Debt	-0.37	-0.36	-0.6	-0.6	0.05	-0.36	-0.67	-0.6	0.41	0.81	-0.56	-0.37	-0.37	-0.72	-0.89	-0.37	-0.56	-0.87	-0.38	-0.7	-0.62		-0.12	1.0	-0.67	1.0
Net Invested Capital	0.96	0.72	0.56	0.63	0.95	0.72	0.77	0.68	-0.94	-0.57	0.73	0.96	0.96	-0.15	0.36	0.72	0.74	0.44	0.95	0.77	0.55	-0.12		-0.12	0.55	-0.12
Short Long Term Debt	-0.37	-0.36	-0.6	-0.6	0.05	-0.36	-0.67	-0.6	0.41	0.81	-0.56	-0.37	-0.37	-0.72	-0.89	-0.37	-0.56	-0.87	-0.38	-0.7	-0.62	1.0	-0.12		-0.67	1.0
Capital Stock	0.74	0.75	0.94	0.96	0.38	0.75	0.88	0.79	-0.75	-0.96	0.97	0.75	0.75	0.62	0.83	0.76	0.97	0.91	0.76	0.9	1.0	-0.67	0.55	-0.67		-0.67
Non Current Liabilities Other	-0.37	-0.36	-0.6	-0.6	0.05	-0.36	-0.67	-0.6	0.41	0.81	-0.56	-0.37	-0.37	-0.72	-0.89	-0.37	-0.56	-0.87	-0.38	-0.7	-0.62	1.0	-0.12	1.0	-0.67

Click cells to compare fundamentals

MAIA Biotechnology Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:

How To Invest In MAIA

Details

Is MAIA Stock a good investment?

Details

What is MAIA Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.34)

Return On Assets

(1.07)

Return On Equity

(5.60)

The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MAIA Historical Balance Sheet

About MAIA Balance Sheet Analysis

MAIA Biotechnology Balance Sheet Chart

Total Assets

Total Current Liabilities

MAIA Biotechnology balance sheet Correlations

MAIA Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Liab	+ 1.0	Short Long Term Debt Total
Other Stockholder Equity	+ 1.0	Accounts Payable
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Total Liab	- 0.98	Retained Earnings
Capital Stock	- 0.96	Retained Earnings